الفهرس | Only 14 pages are availabe for public view |
Abstract Sofosbuvir is the cornerstone of the current IFN-free regimens for treatment of HCV genotype 4, achieving high sustained virologic response 12 weeks post treatment (SVR12) with a good safety profile. High rates of SVR were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. Aim of work: This study aims to assess the treatment response of naïve non-cirrhotic Egyptian chronic hepatitis C patients to Generic sofosbuvir/ledipasvir combination therapy for either 8 weeks or 12 weeks of therapy patients and methods: The study was conducted on 40 naive patients with HCV genotype 4 without cirrhosis who were randomly assigned to Generic sofosbuvir/ledipasvir for 8 weeks or 12 weeks. The primary end point was sustained virologic response at 12 weeks after the end of therapy. Results: 57.5% of studied patients were females with mean age 39.4 years. There was no significant difference among the 2 groups of patients in pre-treatment demographic, laboratory features, AFP, viral load or fibrosis stage. A more significant reduction of liver enzymes was noticed in group 2. The rate of SVR12 was 100% with 8 weeks of generic sofosbuvir/ledipasvir and 95% with 12 weeks of the same regimen. Conclusion: Generic sofosbuvir/Ledipasvir for 8 weeks was associated with a high rate of SVR12 among previously untreated patients with HCV genotype 4 infection without cirrhosis. No additional benefit was associated with extension of the duration of treatment to 12 weeks |